SABS · SAB Biotherapeutics Inc
United States · RS rating 36 · As of 2026-11-03
| Price | 3.12 USD |
|---|---|
| 1-day change | -5.5% |
| RS rating (overall / 1M / 3M / 12M) | 36 / 59 / 35 / 48 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 10 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +20.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +32.0% |
| Market cap (USD) | $267.0M |